DSM to Supply Cancer Drug for Eisai

By Dan Stanton

- Last updated on GMT

Related tags: Dsm pharmaceutical products, Cancer, Pharmacology

DSM to Supply Cancer Drug for Eisai
Eisai says its US supply agreement with DSM offers an alternate manufacturing facility and ensures a strengthened supply line.

Royal DSM’s contract manufacturing arm, DSM Pharmaceutical Products, has signed a three year master supply agreement with the US arm of Japanese drug developer Eisai. The deal, of which financial details were not given, will see DSM manufacture a number of sterile products including the breast cancer vaccine eribulin mesylate, marketed as Halaven.

DSM will shortly begin commercial production at its Greenville, North Carolina facility. In a press statement Shawn Gallagher, President Partnership Management CFU at Eisai said: “This alternate site of manufacturing strengthens the supply reliability of this important product for our patients.”

President of DSM Pharmaceuticals, Laura Parks, added that the company had worked with Eisai from the launch of eribulin mesylate, and “combining the expertise of Eisai in developing innovative medicines with DSM's strength in Good Manufacturing Practices (GMP), and supply chain management will provide critical high quality treatments for patients.”

Keeping Manufacturing Options Open

Quality issues at several manufacturing plants have led to shortages of a number of drugs and some pharma companies are on the lookout for alternative sites to ensure constant supply.

Quality issues caused a shutdown at CMO Ben Venue’s Bedford plant and led to a number of drug shortages including Genzyme’s leukaemia drug Fludara​ and Janssen’s ovarian cancer drug Doxil.

Janssen​ is currently hunting out other CMOs to ensure its drug supply remains full and unrestricted in the wake of Ben Venue’s continual problems as lapses in quality and an increase in regulatory pressures is causing drug companies to rethink how their products are manufactured.

Halaven

Halaven received approval from the FDA (US Food and Drug Administration) in November 2010. Eisai began marketing the agent in the United Kingdom, Germany and other European countries in April 2011.

The drug, derived from marine sponges, is an injectable therapy which inhibits cancer cell growth in breast cancer sufferers.

Related news

Show more

Related products

show more

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Products

View more

Webinars